

**VIVANZA BIOSCIENCES LIMITED**

**(Formerly Known as IVEE INJECTAA LTD )**

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge , Ahmedabad 380 006.

CIN : L24110GJ1982PLC005057


**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2016.**

Part I		(Rs. in Lacs except per share data)					
		Quarter Ended			Nine Month Ended		Year Ended
Particulars		31/12/2016	30/09/2016	31/12/2015	31/12/2016	31/12/2015	31/03/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	(a) Net Income from Operations	48.31	46.70	0.00	94.86	0.00	0.00
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from Operations (net)</b>	<b>48.31</b>	<b>46.70</b>	<b>0.00</b>	<b>94.86</b>	<b>0.00</b>	<b>0.00</b>
2	<b>Expenses</b>						
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	83.87	38.82	0.00	122.69	0.00	0.00
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-41.83	-0.05	0.00	-42.02	0.00	0.00
	(d) Employee benefits expense	12.69	9.96	0.00	32.57	0.00	0.00
	(e) Depreciation and amortisation expense	0.04	0.00	0.00	0.04	0.00	0.00
	(f) Other expenses	10.62	2.07	0.98	17.15	4.78	6.08
	<b>Total Expenses</b>	<b>65.39</b>	<b>50.80</b>	<b>0.98</b>	<b>130.43</b>	<b>4.78</b>	<b>6.08</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>-17.08</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.57</b>	<b>-4.78</b>	<b>-6.08</b>
4	Other Income	0.19	0	0.00	0.19	0.00	0.05
	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from ordinary activities before tax (7-8)</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
10	Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) from ordinary after tax (9-10)</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11-12)</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
14	Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	<b>Net Profit / ( Loss ) after taxes , minority interest and share of profit / ( loss ) of associates ( 13 + 14 + 15 )*</b>	<b>-16.89</b>	<b>-4.10</b>	<b>-0.98</b>	<b>-35.38</b>	<b>-4.78</b>	<b>-6.03</b>
17	Paid-up equity share capital (Face value of ` 10/- each)	255.00	255.00	18.80	255.00	18.80	18.80
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	(16.31)
19.i	<b>Earnings Per Share (before extraordinary items) (not annualised):</b>						
	(a) Basic	-0.66	-0.16	-0.52	-1.39	-2.54	-3.21
	(b) Diluted	-0.66	-0.16	-0.52	-1.39	-2.54	-3.21
19.ii	<b>Earnings Per Share (after extraordinary items) (not annualised):</b>						
	(a) Basic	-0.66	-0.16	-0.52	-1.39	-2.54	-3.21
	(b) Diluted	-0.66	-0.16	-0.52	-1.39	-2.54	-3.21

**Notes:**

- The above standalone unaudited financial results were reviewed by the statutory Auditors , recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on Tuesday 14 February , 2017 .
- Company operates only in single segment i.e.pharmaceuticals related activities
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ending December 31, 2016.
- The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.

For, VIVANZA BIOSCIENCES LIMITED



DIRECTOR

Date : 14/02/2017  
Place : Ahmedabad



# GMCA & Co.

Chartered Accountants

Office : 101, "Parishram", 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Road, Navrangpura,  
Ahmedabad-380 009. Ph. : 079-40037372, E-mail : gmca1973@gmail.com

Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of Vivanza Biosciences Ltd. pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

## Independent Auditors' Review Report

To  
The Board of Directors,  
Vivanza Biosciences Ltd.

We have reviewed the accompanying statement of Standalone Unaudited Financial results of Vivanza Biosciences Ltd. for the quarter ended 31<sup>st</sup> December, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Accounting Standard for Interim Financial Reporting (AS 25), Prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Company's personnel & analytical procedures applied to the financial data & thus provide less assurance than audit. We have not performed an Audit & accordingly we do not express an Audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 14<sup>th</sup> February, 2017



For, GMCA & CO.  
Chartered Accountants  
FRN: 109850W

*M S Patel*  
CA. Mitt S. Patel  
Partner  
Membership No: 163940

**VIVANZA BIOSCIENCES LIMITED**

(Formerly Known as IVEE INJECTAA LTD )

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge , Ahmedabad 380 006.  
CIN : L24110GJ1982PLC005057

**STATEMENT OF CONSOLIDATE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2016.**

Part I		(Rs. in Lacs except per share data)		
		Quarter Ended		Nine Month Ended
Particulars		31/12/2016	30/09/2016	31/12/2016
		Unaudited	Unaudited	Unaudited
1	<b>Income from Operations</b>			
	(a) Net Income from Operations	48.16	46.70	94.86
	(b) Other Operating Income	0.00	0.00	0.00
	<b>Total Income from Operations (net)</b>	<b>48.16</b>	<b>46.70</b>	<b>94.86</b>
2	<b>Expenses</b>			
	(a) Cost of Materials consumed	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	83.87	38.82	122.69
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-41.97	-0.05	-42.02
	(d) Employee benefits expense	15.71	15.08	40.72
	(e) Depreciation and amortisation expense	0.04	0.00	0.04
	(f) Other expenses	10.61	2.48	17.54
	<b>Total Expenses</b>	<b>68.25</b>	<b>56.33</b>	<b>138.96</b>
	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>-20.09</b>	<b>-9.63</b>	<b>-44.10</b>
4	Other Income	0.19	0	0.19
	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)</b>	<b>-19.90</b>	<b>-9.63</b>	<b>-43.91</b>
6	Finance Costs	0.03	0.01	0.04
	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>-19.93</b>	<b>-9.64</b>	<b>-43.95</b>
8	Exceptional Items	0.00	0.00	0.00
	<b>Profit / (Loss) from ordinary activities before tax (7-8)</b>	<b>-19.93</b>	<b>-9.64</b>	<b>-43.95</b>
10	Tax Expense	0.00	0.00	0.00
	<b>Net Profit / (Loss) from ordinary after tax (9-10)</b>	<b>-19.93</b>	<b>-9.64</b>	<b>-43.95</b>
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00
	<b>Net Profit / (Loss) for the period (11-12)</b>	<b>-19.93</b>	<b>-9.64</b>	<b>-43.95</b>
14	Share of Profit / ( Loss) of associates *	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00
	<b>Net Profit / ( Loss ) after taxes , minority interest and share of profit / ( loss ) of associates ( 13 + 14 + 15 ) *</b>	<b>-19.93</b>	<b>-9.64</b>	<b>-43.95</b>
17	Paid-up equity share capital (Face value of ` 10/- each)	255.00	255.00	255.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-
19.i	<b>Earnings Per Share (before extraordinary items) (not annualised):</b>			
	(a) Basic	-0.78	-0.38	-1.72
	(b) Diluted	-0.78	-0.38	-1.72
19.ii	<b>Earnings Per Share (after extraordinary items) (not annualised):</b>			
	(a) Basic	-0.78	-0.38	-1.72
	(b) Diluted	-0.78	-0.38	-1.72

**Notes:**

- The above consolidate unaudited financial results were reviewed by the statutory Auditors , recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on Tuesday 14 February , 2017 .
- Company operates only in single segment i.e.pharmaceuticals related activities
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ending December 31, 2016.
- Vivanza Lifesciences Private Limited (formerly Fortune Beverages Private Limited) (VLPL) became Wholly Owned Subsidiary of the Company w.e.f. June 17, 2016. Hence, figures for corresponding quarter ended and year to date figures for the previous year and figures for the previous year ended are not available and provided for.

Date : 14/02/2017  
Place : Ahmedabad



For, VIVANZA BIOSCIENCES LIMITED  
*Harshul Keshav*  
DIRECTOR



# GMCA & Co.

Chartered Accountants

Office : 101, "Parishram", 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Road, Navrangpura,  
Ahmedabad-380 009. Ph. : 079-40037372, E-mail : gmca1973@gmail.com

## Independent Auditors' Review Report

To  
The Board of Directors,  
Vivanza Biosciences Limited

We have reviewed the accompanying statement of Consolidated Unaudited Financial results of Vivanza Biosciences Limited (The Holding Company) and its Subsidiary Company (The Holding Company and its Subsidiary Collectively referred to as "The Group") for the quarter ended 31<sup>st</sup> December, 2016, attached herewith, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. This statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Accounting Standard for Interim Financial Reporting (AS 25), Prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of the Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Holding Company's personnel & analytical procedures applied to the financial data & thus provide less assurance than audit. We have not performed an Audit & accordingly we do not express an Audit opinion.

The statement includes the results of the wholly-owned subsidiary, Vivanza Life Sciences Private Limited (The Subsidiary Company)

We did not review the Interim Financial Results of the Subsidiary whose Interim Financial Information reflects NIL Revenue & Rs. 3,02,523/- Net Loss after tax for the Quarter ended 31<sup>st</sup> December, 2016. This interim financial information of the subsidiary have not been audited by the any Auditors rather they have been signed & declared by the Directors of the Company & our report on the statement, in so far as it relates to the amounts and disclosures included in respect of the Subsidiary, is based solely on the Financial Statements signed & declared by the Board of Directors of the Subsidiary Company.

Based on our review conducted as above, and based on consideration of the signed & declared Financial Statements referred in the above paragraph, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting



practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 14<sup>th</sup> February, 2017



For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W

*M. S. Patel*  
CA. Mitt S. Patel  
Partner  
Membership No: 163940